Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0028754 (
obesity
)
124,988
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Despite the fact that gut microbiota is closely associated with
obesity
, few studies have focused on the influences of paraprobiotics as food ingredients on both
obesity
prevention and the gut microbial community. In this study, we evaluated the effects of fragmented
Lactobacillus amylovorus
CP1563 (CP1563) as a paraprobiotic for
obesity
prevention and investigated its effects on the gut microbial community in pre-obese subjects. One hundred sixty-nine healthy subjects with a body mass index from 25.0 to 29.9 kg/m
2
ingested beverages with or without the fragmented CP1563 containing
10-hydroxyoctadecanoic acid
(10-HOA) for 12 weeks. The changes in abdominal, total, visceral, and subcutaneous fatty areas were significantly lower in the CP1563-10-HOA group than in the placebo group at 12 weeks. Furthermore, 16S rRNA gene sequencing of fecal DNA revealed that the changes in the abundances of the genera
Roseburia
and
Lachnospiraceae;
g were significantly greater in the CP1563-10-HOA group than in the placebo group, and the changes in the abundances of the genus
Collinsella
was significantly smaller in the CP1563-10HOA group than in the placebo group. Our results showed that continuous ingestion of the fragmented CP1563 containing 10-HOA reduced abdominal body fat and affected the gut microbial community in pre-obese healthy subjects. Our findings may contribute to the understanding of the relationship between the anti-
obesity
effect of paraprobiotics and gut microbiota.
...
PMID:Daily Intake of Paraprobiotic
Lactobacillus amylovorus
CP1563 Improves Pre-Obese Conditions and Affects the Gut Microbial Community in Healthy Pre-Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Study. 3209 38